Prime Medicine, Inc. Comprehensive Income
Prime Medicine, Inc. (PRME) reported Comprehensive Income of -$42.12 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- Prime Medicine, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$42.12M.
- Prime Medicine, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$49.20M.
- Prime Medicine, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$46.03M.
- Prime Medicine, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$50.54M.
- Prime Medicine, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$201.06M.
- Prime Medicine, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$195.87M.
- Prime Medicine, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$197.76M.
- Prime Medicine, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$122.18M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$42.12M 10-Q · filed 2026-08-06 | -$91.32M 10-Q · filed 2026-08-06 | -$137.35M derived: sum of 3 quarters · filed 2026-08-06 | -$187.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$49.20M 10-Q · filed 2026-05-07 | -$95.23M derived: sum of 2 quarters · filed 2026-05-07 | -$145.77M derived: sum of 3 quarters · filed 2026-05-07 | -$198.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$46.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$96.57M derived: sum of 2 quarters · filed 2026-03-03 | -$149.16M derived: sum of 3 quarters · filed 2026-08-06 | -$201.06M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$50.54M 10-Q · filed 2025-11-07 | -$103.13M derived: sum of 2 quarters · filed 2026-08-06 | -$155.03M 10-Q · filed 2025-11-07 | -$197.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$52.59M 10-Q · filed 2026-08-06 | -$104.49M 10-Q · filed 2026-08-06 | -$146.79M derived: sum of 3 quarters · filed 2026-08-06 | -$199.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$51.91M 10-Q · filed 2026-05-07 | -$94.20M derived: sum of 2 quarters · filed 2026-05-07 | -$146.63M derived: sum of 3 quarters · filed 2026-05-07 | -$201.93M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$42.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$94.72M derived: sum of 2 quarters · filed 2026-03-03 | -$150.03M derived: sum of 3 quarters · filed 2026-03-03 | -$195.87M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$52.43M 10-Q · filed 2025-11-07 | -$107.73M derived: sum of 2 quarters · filed 2025-11-07 | -$153.57M 10-Q · filed 2025-11-07 | -$219.08M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$55.30M 10-Q · filed 2025-08-07 | -$101.14M 10-Q · filed 2025-08-07 | -$166.65M derived: sum of 3 quarters · filed 2025-08-07 | -$217.24M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$45.84M 10-Q · filed 2025-05-08 | -$111.35M derived: sum of 2 quarters · filed 2025-05-08 | -$161.94M derived: sum of 3 quarters · filed 2025-05-08 | -$204.39M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$65.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$116.10M derived: sum of 2 quarters · filed 2025-02-28 | -$158.55M derived: sum of 3 quarters · filed 2025-02-28 | -$197.76M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$50.59M 10-Q · filed 2024-11-12 | -$93.04M derived: sum of 2 quarters · filed 2024-11-12 | -$132.25M 10-Q · filed 2024-11-12 | -$171.47M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$42.45M 10-Q · filed 2024-08-08 | -$81.67M 10-Q · filed 2024-08-08 | -$120.88M derived: sum of 3 quarters · filed 2024-08-08 | -$150.53M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$39.22M 10-Q · filed 2024-05-10 | -$78.43M derived: sum of 2 quarters · filed 2024-05-10 | -$108.08M derived: sum of 3 quarters · filed 2024-05-10 | -$137.55M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$39.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$68.87M derived: sum of 2 quarters · filed 2024-03-01 | -$98.33M derived: sum of 3 quarters · filed 2024-03-01 | -$122.18M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$29.65M 10-Q · filed 2023-11-03 | -$59.12M derived: sum of 2 quarters · filed 2023-11-03 | -$82.97M 10-Q · filed 2023-11-03 | -$145.89M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | -$29.47M 10-Q · filed 2023-08-07 | -$53.31M 10-Q · filed 2023-08-07 | -$116.24M derived: sum of 3 quarters · filed 2023-08-07 | -$132.63M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$23.84M 10-Q · filed 2023-05-11 | -$86.77M derived: sum of 2 quarters · filed 2023-05-11 | -$103.16M derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$62.93M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$79.32M derived: sum of 2 quarters · filed 2023-03-09 | -$165.39M 10-K · filed 2023-03-09 | |
| 2021-09-30 | -$16.39M 10-Q · filed 2022-11-14 | -$102.47M 10-Q · filed 2022-11-14 | ||
| 2020-12-31 | -$3.41M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |